2012 Mass Challenge Winner
2012 Columbia Venture Competition Winner
2012 TiE Competition Winner
2011 MIT 100k First Runner-up
Our platform technology leverages advances in microfluidics and unique extracellular matrix formulations to specifically capture cancer cells from a biopsy sample. Existing methods do not exclude normal, healthy cells during analysis and may lead to misdiagnosis and uncertainty. Cellanyx Diagnostics is unique because of its ability to analyze molecular, biophysical, and phenotypic biomarkers has the potential to guide therapy for patients in all stages of treatment.
- Optimize protocol in prostatecomy samples
- Discriminate samples between cancer and non-cancer
- Confirm prognostic capability by identifying low and high risk cancers
We are fundraising to further develop our platform technology and refine our device design and predictive algorithms. Our goal is to raise $13,500 for a small clinical validation study. Your financial contribution will mitigate the cost of research and support the transfer and translation of academic research into a viable diagnostic service that will positively affect millions of American men.
Your contribution will support a team of scientists and engineers from MIT, Stanford, Columbia, and Boston University and help inspire young Americans to build a foundation for better prostate cancer diagnostics. Moreover, you can help us continue to build support from clinicians, payers, government, industry, and academia. For your contribution, we are offering small, tokens of appreciation and for our most generous contributors, an opportunity to meet our team and have lunch on us at our offices in Boston’s Innovation District.
Early prostate cancer has no symptoms. Most prostate cancers are first identified through a Prostate Specific Antigen (PSA) screening or a digital rectal exam (DRE). In the current treatment paradigm, a tissue biopsy is performed and examined by a pathologist when prostate cancer is suspected. The examination of the grade, or stage, is based on a subjective interpretation of the abnormality of the sample. The pathologist then assigns a Gleason Score, a metric in which a higher Gleason Score indicates large differences from cancerous tissue to normal tissue. However, most patients who receive a low Gleason Score are advised to follow the same treatment plan as patients that receive a high Gleason Score. Moreover, a Gleason Score is only a measure of disease progression to date and is not an indication of how the cells will behave in the future.
We are entrepreneurs, scientists, engineers, and doctors with a passion to serve our community, and we are dedicated to the development of a new diagnostic tool that will improve the quality of care that prostate cancer patients receive.
Our campaign is led by Dr. Ashok Chander, a cell biologist with over 10 years of cancer research experience from Columbia University whose doctoral thesis has brought to fruition a platform technology that addresses the problems in the current treatment paradigm for prostate cancer.
Current prostate cancer diagnostics are inadequate and lack sensitivity and prognostic value. By leveraging lab-on-a-chip technology, novel biomarkers, and predictive algorithms, Cellanyx will offer a predictive, sensitive, and cost effective solution to inform physicians at the radical prostatectomy decision point. Our platform technology will improve the diagnostic process, increase patient quality of life, and reduce healthcare costs.
Our project will show that the interaction of prostate cancer cells with the surrounding microenvironment and the mechanical movement of cancer cells can be invaluable biomarkers and predictive of metastasis. However, to achieve our product development milestones, we need your help.
Our campaign goal is to raise a small amount of capital from the public to complete our first validation study (n < 100). Our long-term goal is to develop the platform into a fully operational diagnostic service and help men worldwide avoid unnecessary treatment, avoid overtreatment, and aid in early detection of metastatic cancer cells.
Being an early-stage biotech startup, we don't have an awesome product that you can wear or brag about like other campaigns, but we do have some unique rewards and we invite you to join us!
WE WANT TO HEAR FROM YOU
Tell us about your story or a person you know who has been affected by prostate cancer.
E-mail us at email@example.com
Thank you for supporting our campaign!
Where is Cellanyx Diagnostics located?
Cellanyx Diagnostics is located in Boston, but a few of our team members are located in San Francisco. We have office space at MassChallenge and lab space at the North Shore InnoVenture.
Who are you collaborating with?
Our collaborators include Boston-area hospitals, Edge Embossing, Northshore InnoVentures (NSIV), and MassChallenge.
Where and how will you get tissue samples for the small validation study?
We will establish a cold chain transport of frozen banked tissue between our collaborators and our lab in Beverly, MA. We have already established a relationship with UPS and FedEx.
Is this technology limited to prostate cancer?
No. Our technology can be used for other cancers. Lung, skin, breast, colon, and uterine cancer are some examples.
In the future, where will your service be available and who will have access?
Cellanyx will provide a lab service to urologists. When a physician is uncertain of a biopsy result, the physician will have the opportunity to gain additional information by sending biopsy samples to Cellanyx's central processing laboratory. Our laboratories will be located in the United States.
Who will pay for this service?
Cellanyx will gain reimbursement approval via the emerging MAAA code.
How long will it take to get results?
Physicians will receive a patient's results approximately 5 days after biopsy.
What are the implications of the results?
Result will be valuable to better understand treatment strategies to optimize clinical outcomes and patient quality of life.
What is your timeline and when will your service be avilable?
To date, MassChallenge has accelerated the establishment of Cellanyx's clinical and laboratory operations during Q4 2012. In Q1 2013, Cellanyx plans to move into the lab to conduct a small validation study. We have several larger studies planned for Q2 through Q4 2013 and will establish clinical significance for diagnostic use by the end of 2013. The soonest our service will be available would be Q1 2016. Your contributions now will help us accelerate our operations for Q1 and Q2 2013.